Social Media Ideas for Leo Pharma

Leo Pharma buys rare skin disease drug in $435M deal

Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod

Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Derm

Derm Anonymous (not verified) Sun, 07/26/2026 - 18:23 field_thread_url https://cafepharma.com/boards/threads/derm.714954/ board name...

Derm

Derm Anonymous (not verified) Fri, 07/24/2026 - 18:22 field_thread_url https://cafepharma.com/boards/threads/derm.714954/ board name...

Derm

Derm Anonymous (not verified) Tue, 08/18/2026 - 03:36 field_thread_url https://cafepharma.com/boards/threads/derm.690595/ board name...

<![CDATA[FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV,...

Dermatology launch

Dermatology launch Anonymous (not verified) Thu, 07/16/2026 - 12:16 field_thread_url https://cafepharma.com/boards/threads/dermatology-launch.716833/...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Sona Dermatology Introduces Ageless AI: Visualize Your Results Before Treatment with Cutting-Edge Technology

SЕЌna Dermatology enhances the cosmetic experience with Ageless AI, allowing patients to visualize their potential results before undergoing laser skin resurfacing and other aesthe...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

Bristol Myers Squibb launches Relopduo, its fixed-dose combination for skin cancer, in India

The dermatology-cancer drug received USFDA approval in 2022 for the treatment of adult and paediatric patients

Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus

Laboratoires Pierre Fabre, the world’s second-largest dermo-cosmetics company and one of Europe’s leading pharmaceutical groups, announced Aug. 25 the appointment of Nicolas Zombré...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

Galderma Group AG 2026 Q2 - Results - Earnings Call Presentation

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

<![CDATA[Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons]]>

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor lande...

Galderma Opens New Headquarters in Miami to Support US and Latin American Operations

The facility features a dedicated training space for healthcare professionals and supports the company’s long-term investment in the dermatology market.

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

Novo Nordisk: The Oral Wegovy Promise